Browse by author
Lookup NU author(s): Dr Sean Colloby, Professor John O'Brien, Professor John-Paul TaylorORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Alzheimer's disease (AD) is characterized by widespread degeneration of cholinergic neurons, particularly in the basal forebrain. However, the pattern of these deficits and relationship with known brain networks is unknown. In this study, we sought to clarify this and used 123I-5-iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (1235IA-85380) single photon emission computed tomography to investigate spatialcovariance of α4β2 nicotinic acetylcholine receptors in AD and healthy controls. Thirteen AD and 16 controls underwent 1235IA-85380 and regional cerebral blood flow (99mTc-exametazime) single photon emission computed tomography scanning. We applied voxel principal component (PC) analysis, generating series of principal component images representing common intercorrelated voxels across subjects. Linear regression generated specific α4β2 and regional cerebral blood flow covariance patterns that differentiated AD from controls. The α4β2 pattern showed relative decreased uptake in numerous brain regions implicating several networks including default mode, salience, and Papez hubs. Thus, as well as basal forebrain and brainstem cholinergic system dysfunction, cholinergic deficits mediated through nicotinic acetylcholine receptors could be evident within key networks in AD. These findings may be important for the pathophysiology of AD and its associated cognitive and behavioral phenotypes.
Author(s): Colloby SJ, Field RH, Wyper DJ, O'Brien JT, Taylor JP
Publication type: Article
Publication status: Published
Journal: Neurobiology of Aging
Year: 2016
Volume: 47
Pages: 83-90
Print publication date: 01/11/2016
Online publication date: 30/07/2016
Acceptance date: 22/07/2016
Date deposited: 23/09/2016
ISSN (print): 0197-4580
ISSN (electronic): 1558-1497
Publisher: Elsevier
URL: http://dx.doi.org/10.1016/j.neurobiolaging.2016.07.017
DOI: 10.1016/j.neurobiolaging.2016.07.017
Altmetrics provided by Altmetric